Venture-Backed Dicerna Cuts First Pharma Deal as Prelude to 'B' Round
This article was originally published in The Pink Sheet Daily
Executive Summary
The startup takes preclinical money from Kyowa Hakko Kirin to target cancer with its alternative RNAi method.